Overview

A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies

Status:
Unknown status

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of open-label ganaxolone as adjunctive therapy for uncontrolled seizures in female children with PCDH19 mutation and other rare genetic epilepsies in an open-label proof-of-concept study.

Phase:

Phase 2

Details

Lead Sponsor:

Marinus Pharmaceuticals

Treatments:

Ganaxolone
Pregnanolone